Company Description

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases in the United States.

The company product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren’s Contracture; and Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain.

180 Life Sciences Corp. is headquartered in Palo Alto, California.

ETHZilla Corporation

Country	United States
Industry	Asset Management - Cryptocurrency
Sector	Financials
Employees	4
CEO	Lloyd Jordan

Contact Details

Address: Building 4, Suite 200 Palo Alto, California 94306 United States
Phone	650 285 2387
Website	180lifesciences.com

Stock Details

Ticker Symbol	ETHZ
Exchange	NASDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001690080
CUSIP Number	68236V104
ISIN Number	US68236V3024

Key Executives

Name	Position
Lloyd Jordan	Chief Executive Officer
Eric Van Lent	Chief Financial Officer